Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: RETRACTED ARTICLE: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo

Figure 2

Expression of NF-κB-p65 in HepG2.2.15 cells. A: Detection of NF-κB-p65 expression in cells by immunofluorescence staining. NF-κB p65 (green) was expressed in HepG2.2.15 cells. BM-06 and poly(I:C) induced TLR3-activated HepG2.2.15 cells expressing NF-κB levels predominating in the nucleus fraction. The effect of BM-06 was better than the poly(I:C). B: Western blot analysis of dsRNA induced TLR3-activated HepG2.2.15 cells expressing NF-κB levels predominating in the cytoplasmic fraction. Cytoplasmic and nuclear fractions were assayed for NF-κB protein (α-tubulin, cytoplasmic marker; lamin B, nuclear marker).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us